

## საქართველოს სტანდარტი

სსკ: 07.100.10; 11.080.01

ჯანმრთელობის დაცვის პროდუქტების სტერილიზაცია -  
მიკრობიოლოგიური მეთოდები - ნაწილი 3: ბაქტერიული ენდოტოქსინის  
გამოცდა

სსტ ისო 11737-3:2023/2024

საინფორმაციო მონაცემები

1 მიღებულია და დაშვებულია სამოქმედოდ: სსიპ-საქართველოს სტანდარტებისა და მეტროლოგიის ეროვნული სააგენტოს გენერალური დირექტორის 15/02/2024 წლის № 12 განკარგულებით

2 მიღებულია „თავფურცლის“ თარგმნის მეთოდით: სტანდარტიზაციის საერთაშორისო ორგანიზაციის (ისო) სტანდარტი ისო 11737-3:2023 „ჯანმრთელობის დაცვის პროდუქტების სტერილიზაცია - მიკრობიოლოგიური მეთოდები -ნაწილი 3: ბაქტერიული ენდოტოქსინის გამოცდა“

3 პირველად

4 რეგისტრირებულია: სსიპ-საქართველოს სტანდარტებისა და მეტროლოგიის ეროვნული სააგენტოს რეესტრში: 15/02/2024 წლის №268-1.3-033945

წინამდებარე სტანდარტის ნებისმიერი ფორმით გავრცელება სააგენტოს ნებართვის გარეშე აკრძალულია

საინფორმაციო ნაწილი. სრული ტექსტის სანახავად შეიძინეთ სტანდარტი.

INTERNATIONAL  
STANDARD

ISO  
11737-3

First edition  
2023-06

---

---

**Sterilization of health care products —  
Microbiological methods —**

**Part 3:  
Bacterial endotoxin testing**

*Stérilisation des produits de santé — Méthodes microbiologiques —  
Partie 3: Essai des endotoxines bactériennes*

საინფორმაციო ნაწილი. სრული ტექსტის სანახავად შეიძინეთ სტანდარტი.



Reference number  
ISO 11737-3:2023(E)

© ISO 2023



**COPYRIGHT PROTECTED DOCUMENT**

© ISO 2023

All rights reserved. Unless otherwise specified, or required in the context of its implementation, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office  
CP 401 • Ch. de Blandonnet 8  
CH-1214 Vernier, Geneva  
Phone: +41 22 749 01 11  
Email: [copyright@iso.org](mailto:copyright@iso.org)  
Website: [www.iso.org](http://www.iso.org)

Published in Switzerland

# Contents

Page

<b>Foreword</b> .....	<b>v</b>
<b>Introduction</b> .....	<b>vi</b>
<b>1 Scope</b> .....	<b>1</b>
1.1 Inclusions .....	1
1.2 Exclusions .....	1
<b>2 Normative references</b> .....	<b>1</b>
<b>3 Terms and definitions</b> .....	<b>1</b>
<b>4 General requirements</b> .....	<b>7</b>
<b>5 Selection of products</b> .....	<b>8</b>
5.1 General .....	8
5.2 Selection of product units .....	8
<b>6 Methods for BET</b> .....	<b>9</b>
6.1 General .....	9
6.2 Consideration of an applicable endotoxin limit .....	10
6.2.1 Endotoxin limit .....	10
6.2.2 Calculation of endotoxin limit for the extract solution .....	10
6.2.3 Maximum valid dilution (MVD) .....	10
6.3 Critical test parameters .....	11
6.3.1 Temperature .....	11
6.3.2 Time .....	11
6.3.3 pH .....	11
6.4 Equipment and materials .....	11
6.5 Reagents .....	12
<b>7 Method suitability for BET (BET validation)</b> .....	<b>12</b>
7.1 General .....	12
7.2 Product and test method suitability .....	12
7.2.1 Gel-clot technique .....	12
7.2.2 Kinetic and end point methods (chromogenic and turbidimetric techniques) .....	13
7.3 Sample preparation .....	14
7.3.1 General .....	14
7.3.2 Solid health care products .....	14
7.3.3 Aqueous health care products .....	15
7.3.4 Sample interference .....	15
7.4 Reagent and analyst qualification .....	15
7.4.1 Gel-clot technique reagent qualification .....	15
7.4.2 Kinetic and end point method reagent qualification .....	15
7.4.3 Analyst qualification .....	16
<b>8 Routine testing, monitoring and interpretation of data</b> .....	<b>16</b>
8.1 Routine testing .....	16
8.1.1 Gel-clot limit test .....	16
8.1.2 Gel-clot assay .....	16
8.1.3 Kinetic and end point methods (chromogenic and turbidimetric) .....	17
8.2 Monitoring (test frequency) .....	17
8.3 Interpretation of results .....	17
8.3.1 General .....	17
8.3.2 Gel clot methods .....	18
8.3.3 Kinetic and end point methods .....	18
8.4 Data analysis .....	18
8.5 Statistical methods .....	18
<b>9 Maintenance of the BET method</b> .....	<b>18</b>
9.1 General .....	18

9.2	Changes to either the product or manufacturing process, or both .....	18
9.3	Changes to the BET method.....	19
<b>10</b>	<b>Alternatives to batch testing.....</b>	<b>19</b>
10.1	General.....	19
10.2	Criteria for establishing alternatives to batch testing.....	19
10.3	Manufacturing process assessment.....	20
	10.3.1 Quality planning of manufacturing processes .....	20
	10.3.2 Process design.....	20
	10.3.3 Process control.....	20
10.4	Change control.....	21
10.5	Maintenance of risk assessment.....	21
<b>Annex A (informative) Guidance on bacterial endotoxin testing (following the subclauses in this document) .....</b>		<b>22</b>
<b>Annex B (informative) History and background on the bacterial endotoxins test (BET) .....</b>		<b>42</b>
<b>Annex C (informative) Guidance on out of specified limits (OSL) and failure investigation .....</b>		<b>46</b>
<b>Annex D (informative) Guidance on in-process monitoring of manufacturing processes or component testing.....</b>		<b>50</b>
<b>Annex E (informative) Guidance on conducting a risk assessment to support alternatives to batch testing.....</b>		<b>53</b>
<b>Annex F (informative) Typical assignment of responsibilities .....</b>		<b>58</b>
<b>Bibliography.....</b>		<b>60</b>

საინფორმაციო ნაწილი. სრული ტექსტის საწინააღმდეგო შეიქმნა სტანდარტის

## Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see [www.iso.org/directives](http://www.iso.org/directives)).

ISO draws attention to the possibility that the implementation of this document may involve the use of (a) patent(s). ISO takes no position concerning the evidence, validity or applicability of any claimed patent rights in respect thereof. As of the date of publication of this document, ISO had not received notice of (a) patent(s) which may be required to implement this document. However, implementers are cautioned that this may not represent the latest information, which may be obtained from the patent database available at [www.iso.org/patents](http://www.iso.org/patents). ISO shall not be held responsible for identifying any or all such patent rights.

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT), see [www.iso.org/iso/foreword.html](http://www.iso.org/iso/foreword.html).

This document was prepared by Technical Committee ISO/TC 198, *Sterilization of health care products*.

A list of all parts in the ISO 11737 series can be found on the ISO website.

Any feedback or questions on this document should be directed to the user's national standards body. A complete listing of these bodies can be found at [www.iso.org/members.html](http://www.iso.org/members.html).

## Introduction

A pyrogen is any substance that can induce fever. Testing for pyrogens is required for release of many health care products. Pyrogens can be classified into two groups: microbial (e.g. bacteria, fungi, viruses) and non-microbial (e.g. drugs, device materials, steroids, plasma fractions; see the ISO 10993 series). The predominant pyrogenic contaminants encountered in the manufacturing of health care products are bacterial endotoxins, which are components of the cell walls of Gram-negative bacteria. Although Gram-positive bacteria, fungi, and viruses can be pyrogenic, they do so through different mechanisms (systemic effects) and to a lesser degree than Gram-negative bacteria. Only the Gram-negative bacterial endotoxins test (BET) using amoebocyte lysate reagents from *Limulus polyphemus* or *Tachypleus tridentatus* is covered in this document. Other endotoxin detection methodologies, such as monocyte activation and recombinant Factor C (rFc), are not included (see [B.12](#)) in this document.

Endotoxins are the molecular weight lipopolysaccharide (LPS) components of the outer cell wall of Gram-negative bacteria, that can cause fever, meningitis, and a rapid fall in blood pressure if introduced into the blood stream or certain other tissues of the body. The outer cell wall components, which are composed primarily of proteins, phospholipids and LPS, are constantly released by the cell into the surrounding environment. Endotoxins are ubiquitous in nature, stable, and small enough to pass through conventional sterilizing filters. Sterilization processes will inactivate microorganisms on or in products, but usually do not inactivate endotoxin on products. With controlled processes, endotoxin contamination can be prevented.

The non-pyrogenicity of a health care product can be achieved through the following:

- a) manufacturing techniques that prevent or control endotoxin contamination (e.g. contamination with Gram-negative bacteria);
- b) depyrogenation by endotoxin inactivation (e.g. dry heat) or physical removal (e.g. rinsing, distillation, ultrafiltration).

The purpose of this document is to describe the requirements and guidance for testing for bacterial endotoxins. This includes product required to be non-pyrogenic based on either intended use or non-pyrogenic label claim, or both. Guidance is also provided on selection of product units, method suitability, use of techniques for routine testing, interpretation of test results, and alternatives to batch testing and risk assessment. Information on the following is provided in the annexes:

- guidance on bacterial endotoxin testing ([Annex A](#));
- the history and background on the BET ([Annex B](#));
- guidance on out of specified limits (OSL) and failure investigation ([Annex C](#));
- guidance on in-process monitoring of manufacturing or component testing ([Annex D](#));
- guidance on conducting a risk assessment to support alternatives to batch testing ([Annex E](#));
- typical assignment of responsibilities ([Annex F](#)).

This document is based on ANSI/AAMI ST72. Several sections in this document have been restructured and extended or changed from ANSI/AAMI ST72.

საინფორმაციო ნაწილი. სრული ტექსტის სანახავად შეიძინეთ სტანდარტი.